1. Home
  2. VNRX
  3. VNRX News

Latest VolitionRX Limited (VNRX) News on September 7, 2025

VNRX

PR Newswire

3 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
VNRX

PR Newswire

3 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis.
VNRX

Zacks Small Cap Research

3 months ago

VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis.

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VNRX

PR Newswire

4 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones
VNRX

GuruFocus.com

4 months ago

VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones

VNRX

Associated Press Finance

4 months ago

VolitionRX: Q1 Earnings Snapshot

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VNRX

PR Newswire

4 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For
VNRX

GuruFocus.com

4 months ago

VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VNRX

PR Newswire

4 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VNRX

PR Newswire

4 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
VNRX

PR Newswire

4 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
VNRX

GuruFocus.com

5 months ago

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
VNRX

PR Newswire

5 months ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
VNRX

PR Newswire

5 months ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
VNRX

PR Newswire

5 months ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
VNRX

PR Newswire

5 months ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
VNRX

PR Newswire

5 months ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

VNRX

MT Newswires

6 months ago

VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
VNRX

PR Newswire

6 months ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
VNRX

PR Newswire

6 months ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Volition Proudly Sponsors the 44th ISICEM Congress
VNRX

PR Newswire

6 months ago

Volition Proudly Sponsors the 44th ISICEM Congress

VNRX

MT Newswires

6 months ago

VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
VNRX

PR Newswire

6 months ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
VNRX

PR Newswire

6 months ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs
VNRX

Zacks Small Cap Research

6 months ago

VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
VNRX

PR Newswire

6 months ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
VNRX

PR Newswire

6 months ago

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
VNRX

PR Newswire

7 months ago

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
VNRX

PR Newswire

7 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
VNRX

PR Newswire

7 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Volition Issues Business Review 2024
VNRX

PR Newswire

8 months ago

Volition Issues Business Review 2024

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
VNRX

PR Newswire

9 months ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
VNRX

PR Newswire

9 months ago

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
VNRX

PR Newswire

9 months ago

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs.
VNRX

Zacks Small Cap Research

9 months ago

VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs.

VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
VNRX

GuruFocus.com

10 months ago

VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

VNRX

Associated Press Finance

10 months ago

VolitionRX: Q3 Earnings Snapshot

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
VNRX

PR Newswire

10 months ago

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For
VNRX

GuruFocus.com

10 months ago

VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
VNRX

PR Newswire

10 months ago

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Volition Appoints Timothy I. Still as Chairman
VNRX

PR Newswire

10 months ago

Volition Appoints Timothy I. Still as Chairman

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
VNRX

PR Newswire

10 months ago

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
VNRX

PR Newswire

a year ago

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
VNRX

PR Newswire

a year ago

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Volition Appoints Dr. Ethel Rubin as an Independent Director
VNRX

PR Newswire

a year ago

Volition Appoints Dr. Ethel Rubin as an Independent Director

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
VNRX

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th
VNRX

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Volition Hosts KOL Roundtable on Sepsis
VNRX

PR Newswire

a year ago

Volition Hosts KOL Roundtable on Sepsis

VNRX: Nu.Q Vet Test is now available in 17 countries. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR (human cancer detection method) and Nu.Q NET for sepsis. $7.0 million financing completed.
VNRX

Zacks Small Cap Research

a year ago

VNRX: Nu.Q Vet Test is now available in 17 countries. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR (human cancer detection method) and Nu.Q NET for sepsis. $7.0 million financing completed.

VNRX

Associated Press Finance

a year ago

VolitionRX: Q2 Earnings Snapshot

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering
VNRX

PR Newswire

a year ago

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
VNRX

PR Newswire

a year ago

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
VNRX

PR Newswire

a year ago

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Distribution of Nu.Q Vet Test Expected to Expand During 2H 2024; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture-PCR) 2) Nu.Q NET for Sepsis
VNRX

Zacks Small Cap Research

a year ago

VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Distribution of Nu.Q Vet Test Expected to Expand During 2H 2024; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture-PCR) 2) Nu.Q NET for Sepsis

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
VNRX

ACCESSWIRE

a year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
VNRX

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

VNRX

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
VNRX

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

VNRX

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
VNRX

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
VNRX

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
VNRX

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
VNRX

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Lotto 6/49 - $64 million up for grabs in the next draw!
VNRX

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
VNRX

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
VNRX

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
VNRX

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
VNRX

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
VNRX

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
VNRX

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
VNRX

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

VolitionRx Limited to Present at Jefferies Global Healthcare Conference
VNRX

PR Newswire

a year ago

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

VNRX

GuruFocus.com

a year ago

VolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...

VNRX

Associated Press Finance

a year ago

VolitionRX: Q1 Earnings Snapshot

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VNRX

PR Newswire

a year ago

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech

VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis
VNRX

Zacks Small Cap Research

a year ago

VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis

VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript
VNRX

Insider Monkey

a year ago

VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
VNRX

PR Newswire

a year ago

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
VNRX

PR Newswire

a year ago

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

Volition appoints Dr Andrew Retter as Chief Medical Officer
VNRX

PR Newswire

a year ago

Volition appoints Dr Andrew Retter as Chief Medical Officer

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
VNRX

PR Newswire

2 years ago

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

VNRX

Associated Press Finance

2 years ago

First Internet: Q4 Earnings Snapshot

Princeton Bancorp, Inc. Announces Declaration of a $0.30 Quarterly Cash Dividend
VNRX

PR Newswire

2 years ago

Princeton Bancorp, Inc. Announces Declaration of a $0.30 Quarterly Cash Dividend

VNRX

Zacks Small Cap Research

2 years ago

ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform

Peoples Bancorp Announces Special Cash Dividend
VNRX

GlobeNewswire

2 years ago

Peoples Bancorp Announces Special Cash Dividend

Blue Owl Unloads 9 Big Lots Stores for $51M
VNRX

Commercial Observer

2 years ago

Blue Owl Unloads 9 Big Lots Stores for $51M

ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
VNRX

Zacks

2 years ago

ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why

Investors Should Be Encouraged By Euroseas' (NASDAQ:ESEA) Returns On Capital
VNRX

Simply Wall St.

2 years ago

Investors Should Be Encouraged By Euroseas' (NASDAQ:ESEA) Returns On Capital

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances
VNRX

InvestorPlace

2 years ago

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Westport Appoints Dan Sceli as Chief Executive Officer
VNRX

CNW Group

2 years ago

Westport Appoints Dan Sceli as Chief Executive Officer

VNRX

Business Wire

2 years ago

Mesabi Trust Press Release

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
VNRX

GlobeNewswire

2 years ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year
VNRX

Business Wire

2 years ago

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year

AngioDynamics Inc (ANGO) Reports Fiscal 2024 Second Quarter Results and Revises Full-Year Guidance
VNRX

GuruFocus.com

2 years ago

AngioDynamics Inc (ANGO) Reports Fiscal 2024 Second Quarter Results and Revises Full-Year Guidance

Volition Issues Business Review 2023
VNRX

PR Newswire

2 years ago

Volition Issues Business Review 2023

Share on Social Networks: